Graham Blakey
Executive Director
Graham has provided leadership in Clinical Pharmacology through strategic thinking and a creative approach to clinical study design.
Graham Blakey
Graham’s career has focused upon the investigation of the clinical pharmacology of new drugs and novel formulations with particular expertise in the transition of novel molecules from discovery into humans.
He is experienced in a number of PK methodologies and has used these across the drug development spectrum. Firstly for AstraZeneca, where he was a Principal Scientist and latterly in a consultative capacity. Graham is a strategic thinker and an advocate of creative and efficient clinical study design. He has applied these principles to many global drug development projects in several therapeutic areas. On many occasions Graham has contributed directly to interactions with the Regulatory Agencies. His skills have involved him in various patent cases where he has acted as an expert witness in several jurisdictions.
Graham has developed professional PK training courses for both experts and non-experts working in the pharmaceutical and bioscience sectors. Additionally, he has provided PK teaching on a number of undergraduate and postgraduate degree courses.
Graham is a pharmacist. He has an MSc in Clinical Pharmacology and a PhD from the Universities of Glasgow and Manchester respectively.
Rachael White
Executive Director
Rachael has provided strategic leadership in DMPK and Clinical Pharmacology from drug discovery through to clinical development.
Rachael White
Rachael’s experience spans drug discovery through to clinical development with a focus in DMPK and Clinical Pharmacology. She has provided strategic and operational leadership for both pre-clinical (DMPK) and clinical pharmacology programmes. Rachael is task oriented and an accomplished project and departmental manager. In these roles she was responsible for design and interpretation, operational oversight, and delivery of projects to time, budget, and appropriate quality standards. In Bioanalysis, Rachael has been the outsourcing manager overseeing the scientific and GLP conduct of bioanalytical study phases outsourced to Contract Research Organisations (CRO).
Rachael has worked for AstraZeneca, Organon Laboratories and Sanofi as well as the CRO, Quotient Clinical. This has provided Rachael with global experience across many products, therapeutic areas, and the varied challenges of drug development.
Rachael started her scientific career at the University of Sheffield where she graduated with a BSc (Hons) in Biochemistry.
Maja Szramowska
Senior Scientist
Maja is an experienced PK scientist with an understanding of drug development from discovery through to the clinic.
Maja Szramowska
Maja is an experienced PK scientist with an understanding of drug development from discovery through to the clinic.
Maja worked at Xenogesis and latterly at Sygnature Discovery. She is an experienced bioanalyst with expertise in method development of LC-MS assays to determine novel drug concentrations generated from pre-clinical DMPK activities. Maja is an experienced user of Phoenix WinNonlin to generate PK parameters from both pre-clinical and clinical pharmacology studies. At PharmaKinetic Maja is furthering her project management skills through acting as the point of contact for several of our clients.
Maja holds an MSci in Biochemistry from the University of Birmingham.
Mari Smith
Research Scientist
Mari has a keen scientific curiosity and brings an attention to detail to her role as a PK Scientist.
Mari Smith
Mari has a keen scientific curiosity and brings an attention to detail to her role as a PK Scientist.
Pharmaceutical industry experience has been gained though placements at 3M and Plasgene Ltd. In her role as a Health and Safety Co-ordinator at the University of Birmingham Mari gained proficiency implementing safe working practices across the research laboratories. Skills gained working in this regulated environment are being directly applied to the Quality Management System within PharmaKinetic, thereby ensuring the PK analyses undertaken are robust and comply with GCP principles.
Mari holds an MSci in Biochemistry from the University of Birmingham.
Pete White
VP Bioanalytical
Pete has expertise in Drug Metabolism, PK and Bioanalysis along with extensive experience in project management.
Pete White
Pete has expertise in Drug Metabolism, Pharmacokinetics and Bioanalysis combined with extensive project management experience.
Pete has broad experience within the bioanalytical field and is a highly competent user of LC-MS, LC-MS/MS, ICP-MS, Orbitrap, QTof and Synapt G2 instrumentation. Throughout his career Pete has been responsible for the advanced method development of large and small molecules in a variety of Pharma environments. These include AstraZeneca and Organon along with several service providers such as Quotient Clinical, Xenogesis and latterly Sygnature Discovery. Pete has successfully supported drug development in the areas of pre-clinical, clinical bioanalytical and ADME. He brings a scientific and pragmatic approach to the management of bioanalytical projects.
Pete holds a BSc (Hons) in Applied Biochemical Sciences from Ulster University.
Helen Walker
Clinical Pharmacology Associate
Helen is an experienced Clinical Pharmacologist offering a pragmatic and critical approach to drug development.
Helen Walker
Helen offers a pragmatic and critical approach to drug development. Her areas of expertise include: DMPK, design and interpretation of Phase I programmes and particularly clinical pharmacology studies (ADME & IV) using microtracers and biomarkers. Helen has extensive experience of providing regulatory and strategic advice to support drug programmes throughput all stages of research and development.
Helen is a successful manager having overseen a global team of Project Leaders, who were responsible for delivering the regulatory and clinical pharmacology and DMPK package for drugs across a number of therapeutic areas. Her recent consulting role uses innovative clinical study design to maximise the data return for clients.
Helen has worked for a number of companies including AstraZeneca and the CRO Quotient Sciences. She holds a BSc in Biomedical Sciences and a PhD in In Vitro DMPK, both from the University of Bradford.